Page 317 - Read Online
P. 317

Cervantes-Gracia et al. Vessel Plus 2020;4:27  I  http://dx.doi.org/10.20517/2574-1209.2020.22                               Page 15 of 19

               36.   Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, et al. Global, regional, and national age-sex-specific mortality for 282 causes
                   of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet
                   2018;392:1736-88.
               37.   Astin F, Jones K, Thompson DR. Prevalence and patterns of anxiety and depression in patients undergoing elective percutaneous
                   transluminal coronary angioplasty. Heart Lung 2005;34:393-401.
               38.   Chhabra L, Zain MA, Siddiqui WJ. Angioplasty. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
               39.   Nadolski GJ, Stavropoulos SW. Contrast alternatives for iodinated contrast allergy and renal dysfunction: options and limitations. J Vasc
                   Surg 2013;57:593-8.
               40.   Schraeder R. Contrast media selection in interventional cardiology. J Clin Basic Cardiol 2001;4:245-8.
               41.   Al Shammeri O, Garcia LA. Thrombolysis in the age of primary percutaneous coronary intervention: mini-review and meta-analysis of
                   early PCI. Int J Health Sci (Qassim) 2013;7:91-100.
               42.   Barauskas M, Unikas R, Tamulenaite E, Unikaite R. The impact of clinical and angiographic factors on percutaneous coronary
                   angioplasty outcomes in patients with acute ST-elevation myocardial infarction. Arch Med Sci Atheroscler Dis 2016;1:e150-7.
               43.   Darvishpour A, Javadi-Pashaki N, Salari A, Sadeghi T, Taleshan-Nejad M. Factors associated with quality of life in patients undergoing
                   coronary angioplasty. Int J Health Sci (Qassim) 2017;11:35-41.
               44.   Kim MJ, Jeon DS, Gwon HC, Kim SJ, Chang K, et al. Health-related quality-of-life after percutaneous coronary intervention in patients
                   with UA/NSTEMI and STEMI: the Korean multicenter registry. J Korean Med Sci 2013;28:848-54.
               45.   Mandal A, Paudel MS, Kafle P, Khalid M, Bhattarai B, et al. Contrast-induced nephropathy following percutaneous coronary intervention
                   at a tertiary cardiac center in Nepal. Cureus 2018;10:e3331.
               46.   Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC/EACTS Guidelines on Myocardial Revascularization: The Task
                   Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic
                   Surgery (EACTS) Developed With the Special Contribution of the European Association of Percutaneous Cardiovascular Interventions
                   (EAPCI). Eur Heart J 2014;35:2541-619.
               47.   Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J
                   Med 1990;89:615-20.
               48.   Diamantopoulos A, Patrone L, Santonocito S, Theodoulou I, Ilyas S, et al. Carbon dioxide angiography during peripheral angioplasty
                   procedures significantly reduces the risk of contrast-induced nephropathy in patients with chronic kidney disease. CVIR Endovasc
                   2020;3:9.
               49.   Ghumman SS, Weinerman J, Khan A, Cheema M, Levin D, et al. Contrast-induced nephropathy following peripheral angiography
                   with carbon dioxide versus iodinated contrast media: a systematic review and meta-analysis of current literature. J Am Coll Cardiol
                   2017;69:2088.
               50.   Andreis A, Budano C, Levis M, Garrone, P, Usmiani T, et al. Contrast-induced kidney injury: how does it affect long-term cardiac
                   mortality? J Cardiovasc Med 2017;18:908-15.
               51.   Neyra JA, Shah S, Mooney R, Jacobsen G, Yee J, et al. Contrast-induced acute kidney injury following coronary angiography: a cohort
                   study of hospitalized patients with or without chronic kidney disease. Nephrol Dial Transplant 2013;28:1463-71.
               52.   Schilp J, De Blok C, Langelaan M, Spreeuwenberg P, Wagner C. Guideline adherence for identification and hydration of high-risk
                   hospital patients for contrast-induced nephropathy. BMC Nephrol 2014;15:2.
               53.   Haq MFU, Yip CS, Arora P. The conundrum of contrast-induced acute kidney injury. J Thorac Dis 2020;12:1721-7.
               54.   Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, et al. Contrast-induced nephropathy in patients undergoing primary
                   angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1780-5.
               55.   Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, et al. A simple risk score for prediction of contrast-induced nephropathy after
                   percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004;44:1393-9.
               56.   Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, et al. Contemporary incidence, predictors, and outcomes of acute kidney
                   injury in patients undergoing percutaneous coronary interventions: insights from the NCDR cath-PCI registry. JACC Cardiovasc Interv
                   2014;7:1-9.
               57.   Watabe H, Sato A, Hoshi T, Takeyasu N, Abe D, et al. Association of contrast-induced acute kidney injury with long-term cardiovascular
                   events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention. Int J
                   Cardiol 2014;174:57-63.
               58.   Berwanger O. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography:
                   Main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation 2011;124:1250-9.
               59.   Bolognese L, Falsini G, Schwenke C, Grotti S, Limbruno U, et al. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-
                   induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary
                   percutaneous coronary intervention. Am J Cardiol 2012;109:67-74.
               60.   Mohammed NA, Rafie I, Mahfouz A, Achkar K, Hajar R. Contrast-induced nephropathy. Heart Views 2013;14:106-16.
               61.   McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin 2005;21:261-80.
               62.   Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, et al. Contrast-induced nephropathy: basic concepts,
                   pathophysiological implications and prevention strategies. Pharmacol Ther 2017;180:99-112.
               63.   Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation 2010;122:2451-5.
               64.   Morcos R, Kucharik M, Bansal P, Al Taii H, Manam R, et al. Contrast-induced acute kidney injury: review and practical update. Clin Med
                   Insights Cardiol 2019;13:1179546819878680.
   312   313   314   315   316   317   318   319   320   321   322